Editors' welcome and a working definition for a multiple sclerosis cure

Multiple Sclerosis and Related Disorders

Volumn 2, Issue 2, 2013, Pages 65-67

  Banwell, Brenda ^a   Giovannoni, Gavin ^a   Hawkes, Christopher ^a   Lublin, Fred ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BETA INTERFERON; DACLIZUMAB; MITOXANTRONE;

DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG USE; EDITORIAL; GRAY MATTER; HUMAN; LICENCE; MIGRAINE; MULTIPLE SCLEROSIS; PATIENT EDUCATION; PHYSICAL ABUSE; PRESCRIPTION; RECURRENT DISEASE; RELAPSE; RISK FACTOR; SCIENTIFIC LITERATURE; SEXUAL ABUSE;

EID: 84872827396     PISSN: 22110348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msard.2012.12.001     Document Type: Editorial

References (21)

1. I. Borges, and C. Shea The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis Multiple Sclerosis and Related Disorders 2 2012 33 140
2. A. Chaudhuri, and P. Behan Lessons from clinical trials of alemtuzumab in multiplesclerosis Multiple Sclerosis and Related Disorders 2 2013 92 95
3. J.A. Cohen, and A.J. Coles Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial Lancet 380 9856 2012 1819 1828
4. A.J. Coles, and D.A. Compston Alemtuzumab vs. interferon beta-1a in early multiple sclerosis The New England Journal of Medicine 359 17 2008 1786 1801
5. A.J. Coles, and C.L. Twyman Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial Lancet 380 9856 2012 1829 1839
6. A. Gelfand, and J. Gelf Migraine and multiple sclerosis: epidemiology and approach to treatment Multiple Sclerosis and Related Disorders 2 2013 73 79
7. Genzyme. Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis. 2012:1-3.
8. S.L. Gerson Clozapine - deciphering the risks The New England Journal of Medicine 329 3 1993 204 205
9. G. Giovannoni, and S. Cook Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis The Lancet Neurology 10 4 2011 329 337
10. G. Giovannoni, and R. Gold Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis Multiple Sclerosis and Related Disorders 18 S4 2012 514
11. H.P. Hartung, and R. Gonsette Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial Lancet 360 9350 2002 2018 2025
12. E. Havrdova, and S. Galetta Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study Lancet Neurology 8 3 2009 254 260
13. H Kearney, and K Miszkiel A pilot MRI study of white and grey matter involvement by multiple sclerosis spinal cord lesions Multiple Sclerosis and Related Disorders 2 2013 103 108
14. M. Kremenchutzky, and G.P. Rice The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease Brain 129 Pt 3 2006 584 594
15. J. Laurance Neurologists appeal to health secretary over withdrawal of drug for MS patients British Medical Journal 345 2012 e7449
16. M. Magyarin, and H. Søndergaard Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIRstudy) Multiple Sclerosis and Related Disorders 2 2013 141 146
17. S. Ramachandrana, and R. Strangea Progression of disability in multiple sclerosis: a study of factors in fluencing median time to reach an EDSS value Multiple Sclerosis and Related Disorder 2 2013 109 116
18. Sanofi. Discontinuation of licensed supplies of alemtuzumab (Mabcampath), In press.
19. J. Shapiro, and A. Wiglesworth Views on disclosing mistreatment: a focus group study of differencesbetween people with MS and their caregivers Multiple Sclerosis and Related Disorders 2 2013 96 102
20. S. Taheria, and G. Rosenberg Quantification of blood-to-braintransfer rate in multiple sclerosis Multiple Sclerosis and Related Disorders 2 2013 124 132
21. J. Toro, and S. Cardenas Multiple sclerosis in Colombia and other Latin American Countries Multiple Sclerosis and Related Dis-orders 2 2013 80 89